Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMMUTOL

Financiado

Cerrado

ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE...

ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long. Thus, there is an unmet need for safe and e... ver más

30/04/2027

FONDAZIONE TELETHO...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-14

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

FONDAZIONE TELETHON ETS

1.34M€ | Lider

KLINIKUM DER UNIVERSITAET RE...

907.19K€ | Participante

Stichting Sanquin Bloedvoorz...

606.41K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DC cancer Development and immunological control of dendritic cell canc... 183K€ Cerrado

BES-2010-030033 TERAPIA CON CELULAS DENDRITICAS TOLEROGENICAS EN LA ENFERMED... 43K€ Cerrado

TIPPDECRA Tolerogenic immunotherapy with peptide pulsed dendritic cell... 183K€ Cerrado

DCMERT The Role of Dendritic Cell Subsets in the Maintenance of Eff... 283K€ Cerrado

ITREGDIFFERENTIATION Kinetic analysis of molecular profiles during human induced... 198K€ Cerrado

EEBB-I-12-03859 TERAPIA CON CELULAS DENDRITICAS TOLEROGENICAS EN LA ENFERMED... 10K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-04-14
Fecha Fin: 2027-04-30

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the cause of the disease and are required life-long. Thus, there is an unmet need for safe and effective therapies for these diseases, which are well-tolerated and targeting the cause of disease. Tolerogenic dendritic (DC) cell-based therapies, offer the possibility of restoring immune regulation leading to long-lasting effects. Vitamin (Vit)D3-modified tolerogenic DC have been recently applied to Multiple Sclerosis (MS) patients in Phase I trials, demonstrating safety, tolerability, feasibility, and preliminary evidence of an effect. Molecular characterization of VitD3DC from MS patients suggests that they own less tolerogenic properties than those from healthy individuals. Thus, correcting these deficiencies through gene transfer could improve their effectiveness. The aim of IMMUTOL is the fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches. Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products. Results will lead to design of a clinical protocol according to the regulatory requirements for the first-in-man application of engineered tolerogenic VitD3DC in MS patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores